The paper trail

Small print.
Wide open.

A clear path from a claim to the page it came from. Here’s the filing, the research, and how we read it.

The documentS–1Anthropic, PBC26 OCT 2026 · 421 PP.
01The original SEC filingThe authoritative source, in your browser.SEC · HTML 02Download the saved filingThe complete 421-page document, optimized for downloading.PDF · 46 MB 03Download the full researchFindings, customer examples, calculations, and source references.Markdown

Page by page

Go straight to the source.

Page references count physical pages in the saved PDF, starting at 1. The printed filing number is shown separately when available.

Enter a page from 1 to 421. No PDF download needed.

From the filing

PDF page 107

Printed filing page 96 · Extracted page text

View on the SEC
Read the page text
Table of Contents

the  development  process  with  respect  to  such  technology  and  the  care  taken  to  safeguard  against  risks.  We 
cannot be certain that our licensors do not or will not infringe on the intellectual property rights of third parties 
or that our licensors have or will have sufficient rights in the licensed technology or related intellectual property 
rights  in  all  jurisdictions  in  which  we  may  sell  or  offer  our  models,  platform,  and  applications.  Some  of  our 
agreements  with  our  licensors  may  be  terminated  by  them  or  otherwise  provide  for  a  limited  term.  If  we  are 
unable to continue to license technology because of intellectual property infringement claims brought by third 
parties against our licensors or against us, or if we are unable to continue our license agreements or enter into 
new  licenses  on  commercially  reasonable  terms,  our  ability  to  develop  and  sell  our  models,  platform,  and 
applications  containing  or  dependent  on  that  technology  would  be  limited,  and  our  business,  financial 
condition, and results of operations could be adversely affected. 

Additionally, if we are unable to license technology from third parties, we may be forced to acquire or develop 
alternative  technology,  which  we  may  be  unable  to  do  in  a  commercially  feasible  manner,  or  at  all,  and  may 
require us to use alternative technology of lower quality or performance standards. This could limit or delay our 
ability  to  offer  new  or  competitive  offerings  and  increase  our  costs.  Third-party  software  we  rely  on  may  be 
updated  infrequently,  unsupported,  or  include  errors  or  vulnerabilities  that  may  not  be  resolved  in  a  timely 
manner, any of which may result in errors in our own models, platform, and applications or expose our models, 
platform,  and  applications  to  vulnerabilities.  Any  impairment  of  the  technologies  or  of  our  relationship  with 
these third parties could adversely affect our business, financial condition, or results of operations.

Our  development  of  solutions  that  replace  or  reduce  reliance  on  third-party  vendors  may 
expose us to litigation and other disputes.

We develop and deploy proprietary and partner-based solutions that replace, deprecate, or reduce our reliance 
on  third-party  vendors,  including  vendors  that  historically  provided  software,  services,  or  infrastructure 
supporting our business. These vendors may perceive our actions as adversely affecting their business interests 
and  may  assert  claims  against  us,  including  claims  for  breach  of  contract,  intellectual  property  infringement 
(including  patents,  copyrights,  or  trade  secrets),  misuse  of  confidential  or  proprietary  information,  tortious 
interference, or unfair competition.

Such  claims  may  be  asserted  regardless  of  their  merit  and  could  result  in  costly  litigation,  settlements, 
injunctions,  or  restrictions  on  our  ability  to  deploy  or  expand  our  models,  platform,  and  applications. 
Defending against these claims could divert management and key personnel’s attention and resources, require 
significant legal expenditures, and adversely affect our business, financial condition, and results of operations.

We may be subject to claims that we or our employees have misappropriated the intellectual 
property of other companies, particularly as we hire employees from other AI and technology 
companies.

Our success depends in part on our ability to attract and retain highly skilled employees, including engineers, 
data  scientists,  and  researchers  with  experience  in  AI  and  machine  learning.  As  competition  for  AI  talent 
continues to intensify, we have hired and may in the future hire employees who previously worked for or have 
otherwise  been  involved  with  competitors  or  companies  operating  in  related  technology  areas,  and  certain  of 
our employees have left and others may leave to work for such competitors.

These  employees  may  have  had  access  to  proprietary  or  confidential  information,  including  trade  secrets,  of 
their former employers. Although we require employees to comply with confidentiality and intellectual property 
obligations,  we  may  nonetheless  be  subject  to  claims  that  we  or  our  employees  have  misappropriated  or 
improperly  used  trade  secrets  or  other  intellectual  property  of  competitors  or  other  companies.  Such  claims 
may  be  asserted  even  if  we  believe  they  are  without  merit  and  even  in  the  absence  of  any  intentional 
misconduct.

Defending against these claims could be costly, time-consuming, and disruptive, and could divert management 
attention  and  resources  away  from  our  business.  In  addition,  such  disputes  could  result  in  damages, 
settlements, injunctive relief, restrictions on our ability to use certain technologies, limitations on the roles of 
certain  employees,  or  reputational  harm.  Any  of  the  foregoing  could  adversely  affect  our  business,  financial 
condition, and results of operations.

96

Text is provided for reference. Check the original for tables, images, and exact formatting.

Find a section 16 starting points

Section links may begin before the exact paragraph cited in a finding. PDF numbers below use physical pages.

  1. Founders’ letterp. 3SEC
  2. Defined termsp. 12SEC
  3. Prospectus summaryp. 16SEC
  4. Risk factorsp. 38SEC
  5. Management’s discussion & analysisp. 144SEC
  6. Businessp. 190SEC
  7. Governancep. 254SEC
  8. Executive compensationp. 275SEC
  9. Related-person transactionsp. 293SEC
  10. Principal & selling stockholdersp. 299SEC
  11. Capital-stock rightsp. 303SEC
  12. Shares eligible for future salep. 318SEC
  13. Underwritingp. 327SEC
  14. Auditor change & expertsp. 345SEC
  15. Financial statements & notesp. 347SEC
  16. Part II & exhibit indexp. 413SEC

How this was made

Read in full.
Kept in context.

A snapshot of the filing dated , rather than a live record of later events.

3primary reviewers
421pages reviewed
43image instances checked

The review

Three primary reviewers read non-overlapping ranges of the complete main filing. All 43 embedded image instances were transcribed and visually reviewed, including the founders’ letter, charts, and customer case studies. Financial tables were also checked visually for dates, units, and column alignment.

A separate reviewer checked the draft’s calculations, accounting interpretations, and customer qualifications. An additional check covered the later merged findings. The result is 62 findings and 21 customer examples.

The boundary

Companion contracts and other exhibits named in the filing’s index are separate documents and were not independently reviewed. Customer outcomes, technical benchmarks, forecasts, and scientific priority claims remain attributed company or customer disclosures.

The numbers

Dollar figures are U.S. dollars. H1 means the six months ended June 30; Q2 means the three months ended June 30. The 2026 interim financial statements are unaudited. Our calculations show their inputs and are labeled separately from reported values.

Blank fields stay undisclosed. Figures with different periods, conditions, or potentially overlapping scopes are kept separate. An earlier tender price is not an IPO price.

What the evidence labels mean
Reported in filing
A company disclosure, with the period and accounting basis retained.
Company estimate / company claim
An estimate or assertion attributed to the company, with its uncertainty preserved.
Our calculation
A derived figure using cited inputs. It is not a separately reported company metric.
Customer example
A selected case study, with its measurement limits. It is not representative ROI.
Proposed / conditional
A status qualifier for an arrangement that is not yet effective or depends on stated conditions.

About updates. This edition is tied to the October 26, 2026 filing. Any later revision should identify its new source date and preserve the basis of earlier claims.

The footnotes are only the beginning.Explore the findings Read the story
The original, in context

Open the footnote.

A closer look at the filing

Anthropic · Form S-1PDF 1

Opening page 1…

Filed October 26, 2026. PDF is approximately 46 MB and opens only when requested. Section links may precede the exact cited paragraph.